Technical analysis of Perspective Therapeutics, Inc. (CATX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Price Performance
| 1 month | -15.89% |
| 3 months | -8.47% |
| Year-to-date | -1.82% |
| 1 year | -11.18% |
| 3 years | -15.62% |
52-Week Range
| 52-week High | $6.16 |
| 52-week Low | $1.96 |
| Avg Volume (90d) | 1.5M |
Technical Indicators
| SMA 50 | $3.05 |
| SMA 200 | $3.59 |
| Beta | 1.87 |
| 30-day Volatility (annualised) | 58.4% |
| Price vs SMA 50 | -11.6% |
| Price vs SMA 200 | -24.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.73 | |
| 2025-11 | $2.35 | -13.9% |
| 2025-12 | $2.75 | +17.0% |
| 2026-01 | $3.79 | +37.8% |
| 2026-02 | $5.40 | +42.5% |
| 2026-03 | $4.17 | -22.8% |
| 2026-04 | $3.90 | -6.5% |
| 2026-05 | $3.94 | +1.0% |
| 2026-06 | $3.41 | -13.5% |
| 2026-07 | $2.91 | -14.7% |
| 2026-08 | $3.16 | +8.6% |
| 2026-09 | $2.70 | -14.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.18 | $3.02B |
| 2026-09-15 | $0.04 | $67M |
| 2026-09-15 | | $42M |
Price
| Price | $2.88 |
| Market Cap | $328M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.59 |
| EV / EBITDA | -2.37 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 6.61 |